Empower bolsters compounded drug manufacturing capacity with purchase of Eugia site in New Jersey

05 Feb 2024
www.fiercepharma.com
Acquisition
Empower bolsters compounded drug manufacturing capacity with purchase of Eugia site in New Jersey
Preview
Source: FiercePharma
Houston-based Empower Pharma, a manufacturer of compounded drugs, has bolstered its production capacity with the acquisition of a plant in New Jersey from Eugia, a subsidiary of Indian generics manufacturer Aurobindo.
Only a few weeks after an Eugia manufacturing site in New Jersey received an FDA reprimand, it's set to change hands under a newly revealed transaction.
Empower Pharmacy on Monday revealed a plan to buy Eugia's new site in East Windsor. The purchase comes six weeks after the FDA cited Eugia’s site with 10 observations in a Form 483 write-up.
Empower, which produces compounded drugs, will receive Eugia’s 170,000-square-foot plant and will take over its workforce. Along with the plant sale, the companies will form a "contract manufacturing relationship," Empower said.
The site opened last year and boasts bulk manufacturing and automated fill-finish production capabilities, according to Empower.
“We anticipate welcoming the talented team in East Windsor to Empower shortly and we intend to use these capabilities to support our strategic growth initiatives,” Shaun Noorian, the CEO of Empower, said in a release.
Noorian, who founded the company in 2009, added that the acquisition of Eugia's site will allow it to meet the growing demand for compounded drugs.
Eugia is a subsidiary of generics manufacturer Aurobindo.
The manufacture of compounded drugs has come under increased attention with the surge in the popularity of diabetes and obesity drugs. The FDA allows these knockoff treatments to be produced when there is a shortage of a drug, such as the case with Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro.
In its December inspection of Eugia’s plant, the FDA found issues with a construction project that posed a contamination risk. Inspectors also found ceiling leaks and damage to an HVAC system located near an aseptic processing line. Further, the company lacked quality control documentation to prevent contamination, according to the FDA's report.
Empower did not immediately respond to a request for comment on the issues the FDA cited during its December inspection of Eugia’s site.
In 2021, Empower opened a new $55 million plant in Houston. The company called the 85,000-square-foot site one of the largest compounding facilities in the U.S.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.